FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Vashington,	D.C.	20549
· ac g . c ,		_00.0

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Allen Patricia L						2. Issuer Name and Ticker or Trading Symbol Deciphera Pharmaceuticals, Inc. [ DCPH ]								Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner					
(Last)	(Fi	rst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 01/16/2024								Offic belov	er (give title v)		Other (s below)	pecify	
C/O DECIPHERA PHARMACEUTICALS, INC. 200 SMITH STREET					4. It	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person					
(Street)	AM M	A	02451											Form filed by More than One Reporting Person					
(City)	(Si	ate)	(Zip)		- Ru	Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contrastisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction								ion or written	plan th	nat is intended	I to		
		Tab	le I - Non	ı-Deriv	vative	e Se	curitie	s A	cquired, [	Disp	osed o	of, or Be	neficia	ly Owne	d				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)						Execution Date,			Code (In	Transaction Disposed Of (D) (Instr. 3, 4			ed (A) or str. 3, 4 and	Benefi Owned	ies cially Following	Form (D) or	Ownership orm: Direct O) or Indirect ) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
							Code	v	Amount	(A) or (D) Price		Transa	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)			
		1							uired, Di					/ Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/	Date,	4. Transa Code (l 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
			Code V (A) (D) Exercisable Date Title				Title	Amount or Number of Shares											
Stock Option (Right to Buy)	\$14.46	01/16/2024			Α		4,727		(1)	01/	15/2034	Common Stock	4,727	\$10.5783 <sup>(1</sup>	4,727	7	D		

## **Explanation of Responses:**

1. These options were issued upon election by the director to receive her cash board retainer fee of \$50,000 for the FY 2024 in the form of an equity award, in lieu of cash, under the amended and restated non-employee director compensation policy. The shares will vest in four substantially equal installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024.

/s/ Jeffrey M. Held, Attorneyin-Fact

01/18/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.